
<!-- saved from url=(0054)file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM -->
<html><head><meta http-equiv="Content-Type" content="text/html; charset=windows-1251">
<title>
	
	Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension -- Lankeit et al. 31 (5): 1024 -- European Respiratory Journal</title>


	<script language="JavaScript">
	<!--
	function startTarget(windowname,wid,hei) {
	
	var dotpos = windowname.indexOf(".");
	if (dotpos > -1)
	{
	var tempwn = windowname.substring(0,dotpos) +
		windowname.substring(dotpos + 1, windowname.length);
	windowname = tempwn;
	}
	var sizestring = 'width=' + wid + ',height=' + hei;
	window.open('',windowname,'scrollbars,resizable,' + sizestring + '\'');
	}
	// -->
	</script>




	<!-- has inhead tag -->
	
		 
	 
	<script language="JavaScript">
	<!--
	if ( top != self )
	{
		top.location.href = unescape(window.location.pathname);
	}
	//-->
	</script>
	
		
	
		<style type="text/css"><!--
table.content_box_outer_table {
	padding-left:10px;
	padding-bottom:5px;
	padding-top:0px;
	padding-right:0px;
	}

table.content_box_outer_table_in_sidebar_frame {
	padding-left:10px;
	padding-bottom:0px;
	padding-top:10px;
	padding-right:10px;
	}

table.content_box_inner_table {
	background-color:#f0f0f0;
	font-family:Verdana,Arial,Helvetica,sans-serif;
	font-size:65%;
	padding-top:0px;
	padding-left:0px;
	padding-right:0px;
	padding-bottom:5px;
	}

table.content_box_pdfinframes {
	padding-top:0px;
	padding-left:0px;
	padding-right:0px;
	padding-bottom:4px;
	}

td.content_box_title_highlight {
	font-family:"Trebuchet MS",Verdana,Arial,Helvetica,sans-serif;
	font-style:italic;
	color:#ffffff;
	background-color:#01396A;
	font-size:120%;
	font-weight:bold;
	text-align:center;
	padding:1px;
	vertical-align:middle;
	}

td.content_box_title {
	font-family:"Trebuchet MS",Verdana,Arial,Helvetica,sans-serif;
	font-style:italic;
	color:#ffffff;
	background-color:#828282;
	font-size:120%;
	font-weight:bold;
	padding:1px;
	text-align:center;
	vertical-align:middle;
	}

td.content_box_space_between_sections {
	padding-top:2px;
	}

td.content_box_arrow {
	text-align:right;
	padding-left:5px;
	padding-right:0px;
	padding-top:0px;
	padding-bottom:3px;
	}

td.content_box_item {
	text-align:left;
	vertical-align:top;
	padding-left:3px;
	padding-right:5px;
	padding-top:0px;
	padding-bottom:3px;
	}

td.content_box_pdfinframes_citation_cell {
	background-color:#ffffff;
	border:1px #000000 solid;
	padding:3px;
	font-family:Verdana,Arial,Helvetica,sans-serif;
	font-size:65%;
	text-align:left;
	}


font.openaccess {
	font-weight:bold;
	padding-left:3px;
	padding-right:3px;
	background-color:#ffffff;
	}
font.openaccess_open {
	color:#000000;
	}
font.openaccess_access {
	color:#cc0000;
	}
font.openaccess_oa {
	}
.content_box_openaccess_title {
	text-align:center;
	white-space:nowrap;
	background-color:#BABABA;
	}




div.referrer-based-search-line {
	font-family: arial,sans-serif;
	font-size: 0.75em;
	background-color: #009918;
	padding: 3px 25px;
	margin: 0px 4px 5px 0px;
}

div.referrer-based-search-line .search-terms{
	font-weight: bold;
}

div.referrer-based-search-line .collection-name{
	font-style: italic;
}

@media screen,print,handheld
{
    .notonscreen { display: none; }
}
--></style>

	        
<style type="text/css"><!--
	@media screen,print,handheld
{
    .notonscreen { display: none; }
}
--></style>
<!-- ac in the head available -->

 

		
		
	    <script language="javascript">
		<!-- 
	function popwin(url,wid,hei,fromtop,fromleft) {
		var winPref = "channelmode=no,toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=auto,resizable=no,width=" + wid + ",height=" + hei + ",top=" + fromtop + ",left=" + fromleft;
		window.open(url, "popwin", winPref);
	}
	// -->
	</script>
        <script type="text/javascript" src="./674_files/xmlhttprequest.js"></script>
<script type="text/javascript" src="./674_files/utility.js"></script>
<script type="text/javascript" src="./674_files/callback.js"></script>

	
		
	

<meta name="robots" content="nofollow">



<meta name="citation_journal_title" content="European Respiratory Journal">
<meta name="citation_publisher" content="Eur Respiratory Soc">

<meta name="citation_authors" content="Lankeit, M.; Dellas, C.; Panzenbock, A.; Skoro-Sajer, N.; Bonderman, D.; Olschewski, M.; Schafer, K.; Puls, M.; Konstantinides, S.; Lang, I. M.">
<meta name="citation_title" content="Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension">
<meta name="citation_date" content="05/01/2008">
<meta name="citation_volume" content="31">
<meta name="citation_issue" content="5">
<meta name="citation_firstpage" content="1024">
<meta name="citation_id" content="31/5/1024">
<meta name="citation_mjid" content="erj;31/5/1024">
<meta name="citation_doi" content="10.1183/09031936.00100407">
<meta name="citation_abstract_html_url" content="http://erj.ersjournals.com/cgi/content/abstract/31/5/1024">
<meta name="citation_fulltext_html_url" content="http://erj.ersjournals.com/cgi/content/full/31/5/1024">
<meta name="citation_pdf_url" content="http://erj.ersjournals.com/cgi/reprint/31/5/1024.pdf">
<meta name="citation_pmid" content="18256058">

<meta name="dc.Contributor" content="Lankeit, M.">
<meta name="dc.Contributor" content="Dellas, C.">
<meta name="dc.Contributor" content="Panzenbock, A.">
<meta name="dc.Contributor" content="Skoro-Sajer, N.">
<meta name="dc.Contributor" content="Bonderman, D.">
<meta name="dc.Contributor" content="Olschewski, M.">
<meta name="dc.Contributor" content="Schafer, K.">
<meta name="dc.Contributor" content="Puls, M.">
<meta name="dc.Contributor" content="Konstantinides, S.">
<meta name="dc.Contributor" content="Lang, I. M.">
<meta name="dc.Title" content="Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension">
<meta name="dc.Identifier" content="10.1183/09031936.00100407">
<meta name="dc.Date" content="05/01/2008">

<meta name="ROBOTS" content="NOARCHIVE"> 

</head>
<body bgcolor="#FFFFFF" link="#002E55" vlink="#9BC1C7" alink="#E73C2F">


<a name="top"><!-- null --></a>


	
	<table cellpadding="0" cellspacing="0" border="0">
	<tbody><tr>
		<td valign="BOTTOM" nowrap="">
			<a target="_top" style="text-decoration: none" href="file:///C:/"><img border="0" width="220" height="44" alt="ERJ" src="./674_files/title.gif"></a>
			<!--#echo var="HTTP_AD_HTML_STRING_1"-->
			
	<table cellpadding="2" cellspacing="2" width="450">
	<tbody><tr>
		<td align="CENTER" valign="TOP" bgcolor="01396A" nowrap=""><a target="_top" style="text-decoration: none" href="file:///C:/"><font size="-2" color="#FFFFFF" face="trebuchet ms,arial,verdana,helvetica,sans-serif">HOME</font></a></td>
	    <td align="CENTER" valign="TOP" bgcolor="01396A" nowrap=""><a target="_top" style="text-decoration: none" href="file:///C:/help/"><font size="-2" color="#FFFFFF" face="trebuchet ms,arial,verdana,helvetica,sans-serif">HELP</font></a></td>
	    <td align="CENTER" valign="TOP" bgcolor="01396A" nowrap=""><a target="_top" style="text-decoration: none" href="file:///C:/cgi/feedback"><font size="-2" color="#FFFFFF" face="trebuchet ms,arial,verdana,helvetica,sans-serif">FEEDBACK</font></a></td>
	    <td align="CENTER" valign="TOP" bgcolor="01396A" nowrap=""><a target="_top" style="text-decoration: none" href="file:///C:/subscriptions/"><font size="-2" color="#FFFFFF" face="trebuchet ms,arial,verdana,helvetica,sans-serif">SUBSCRIPTIONS</font></a></td>
	    <td align="CENTER" valign="TOP" bgcolor="01396A" nowrap=""><a target="_top" style="text-decoration: none" href="file:///C:/contents-by-date.0.shtml"><font size="-2" color="#FFFFFF" face="trebuchet ms,arial,verdana,helvetica,sans-serif">ARCHIVE</font></a></td>
	    <td align="CENTER" valign="TOP" bgcolor="01396A" nowrap=""><a target="_top" style="text-decoration: none" href="file:///C:/search.dtl"><font size="-2" color="#FFFFFF" face="trebuchet ms,arial,verdana,helvetica,sans-serif">SEARCH</font></a></td>
	    


<td align="CENTER" valign="TOP" bgcolor="01396A" nowrap=""><a target="_top" style="text-decoration: none" href="file:///C:/content/vol31/issue5/"><font size="-2" color="#FFFFFF" face="trebuchet ms,arial,verdana,helvetica,sans-serif">TABLE OF CONTENTS</font></a></td>
	</tr>
	</tbody></table>
	</td>
		<td><img alt=" " width="5" height="5" src="./674_files/spacer.gif"></td>
		<td valign="BOTTOM">
	
	<table cellpadding="0" cellspacing="1" border="0" bgcolor="#000000"><tbody><tr>
	<form method="GET" name="search" action="file:///C:/cgi/search"></form><input type="hidden" name="andorexactfulltext" value="and"><input type="hidden" name="resourcetype" value="1"><input type="hidden" name="disp_type" value=""><input type="hidden" name="sortspec" value="relevance"><td align="CENTER" valign="MIDDLE"> 
		<table cellpadding="1" cellspacing="0" border="0" bgcolor="#DBDBDB"> 
		<tbody><tr>
			<td bgcolor="#01396A"><img alt=" " width="2" height="2" src="./674_files/spacer.gif"></td>
			<td valign="MIDDLE" bgcolor="#01396A" nowrap=""><strong><font size="-2" face="verdana,arial,helvetica,sans-serif" color="#FFFFFF"><em>QUICK</em> SEARCH:&nbsp;</font></strong></td>
			<td align="RIGHT" valign="MIDDLE" bgcolor="#01396A" nowrap=""><a style="text-decoration:none;color:#FFFFFF" href="file:///C:/search.dtl"><font size="-2" face="verdana,arial,helvetica" color="#FFFFFF">&nbsp;[advanced]</font></a></td>
			<td bgcolor="#01396A"><img alt=" " width="2" height="2" src="./674_files/spacer.gif"></td>
		</tr><tr>
			<td bgcolor="#DBDBDB"><img alt=" " width="2" height="2" src="./674_files/spacer.gif"></td>
			<td bgcolor="#DBDBDB" colspan="2">
			<table cellpadding="0" cellspacing="0" border="0"> 
			<tbody><tr>
				<td align="CENTER" valign="BOTTOM"><input type="submit" style="text-decoration:none;font-family:verdana,arial,helvetica;font-size:10px;font-weight:bold;color:#000000;background:#FFFFFF;" value="Go"></td>
				<th align="LEFT" colspan="2"><font size="-2" face="verdana,arial,helvetica,sans-serif" color="#000000"><label for="qsintdefsauthor1">Author:</label><br></font>
					<input type="text" name="author1" id="qsintdefsauthor1" size="9" maxlength="80" value="" style="font-family:verdana,arial,helvetica;font-size:10px;"></th>
				<th align="LEFT" colspan="3"><font size="-2" face="verdana,arial,helvetica,sans-serif" color="#000000"><label for="qsintdefsfulltext">Keyword(s):</label><br></font>
					<input type="text" name="fulltext" id="qsintdefsfulltext" size="16" maxlength="80" value="" style="font-family:verdana,arial,helvetica;font-size:10px;"></th>
			</tr><tr>
				<th><font size="-2" face="verdana,arial,helvetica,sans-serif" color="#000000"><label for="qsintdefspubdate_year">Year:</label>&nbsp;</font></th>
				<td><input type="text" name="pubdate_year" id="qsintdefspubdate_year" size="4" maxlength="4" value="" style="font-family:verdana,arial,helvetica;font-size:10px;"></td>
				<th align="RIGHT"><font size="-2" face="verdana,arial,helvetica,sans-serif" color="#000000"><label for="qsintdefsvolume">Vol:</label>&nbsp;</font></th>
				<td><input type="text" name="volume" id="qsintdefsvolume" size="4" maxlength="10" value="" style="font-family:verdana,arial,helvetica;font-size:10px;"></td>
				<th><font size="-2" face="verdana,arial,helvetica,sans-serif" color="#000000"><label for="qsintdefsfirstpage">Page:</label>&nbsp;</font></th>
				<td><input type="text" name="firstpage" id="qsintdefsfirstpage" size="4" maxlength="10" value="" style="font-family:verdana,arial,helvetica;font-size:10px;"></td>
			</tr> 
			</tbody></table> </td>
			<td bgcolor="#DBDBDB"><img alt=" " width="2" height="2" src="./674_files/spacer.gif"></td>
		</tr>
		</tbody></table></td></tr></tbody></table> 
	 
	</td>
	</tr><tr>
		<td colspan="3"><img alt=" " width="2" height="2" src="./674_files/spacer.gif"><br><!-- subline logic: standard default -->








	
	

	





	
	
	
	 
	


	
	




				<!-- inst auth StSL--><!-- default inst auth  --><font size="-2" face="verdana,arial,helvetica">
	<nobr><strong>Institution: Ukraine:ERJ Sponsored</strong></nobr>
	<nobr><a target="_top" href="file:///C:/cgi/login?uri=%2Fcgi%2Fcontent%2Ffull%2F31%2F5%2F1024">Sign In as Member</a></nobr>
	
		
		
	
	
	</font>
	
 <!-- showauthstring -->
	<!-- INST -->
	<!-- INDV -->
        <!-- SPONSORED -->
	<!-- USER.PFA -->
	<!-- USER.PFABSAIC -->
	<!-- NOT GUEST -->
	

	



 

<hr align="LEFT" size="1" color="#000000" noshade=""></td>
	</tr>
	</tbody></table>











 
	












	






	
		 
      
        <font size="+1" color="A70716"><strong>Published online before print
        
                
                    
                            
                    
                    
                
        
                
                    
                        February 6, 2008, 10.1183/09031936.00100407</strong></font><br>
                    
                
        
        
    

	 
 






 



 
	 
		  
			
	
		<table class="content_box_outer_table" align="right">
		
		
			<tbody><tr>
			<td>
		
	

<!-- beginning of inner table -->
	<table class="content_box_inner_table">
<!-- citation -->

	
		




	

	

	
		
			
<tbody><tr><td class="content_box_title_highlight" colspan="2">This Article</td></tr>

	

	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " width="200" height="1" src="./674_files/spacer.gif"></td></tr>
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
				
				<strong><a href="file:///C:/cgi/content/abstract/31/5/1024">
				Abstract</a></strong>
				 					<img alt="Freely available" width="32" height="7" border="0" src="./674_files/free.gif">
				
	
				</td></tr>
			
		
		
	

	
	
	

	
	
	


	
	
	

	
	
	

	
	
	
	
	
	
	
	
	

	
		
		
	
	
		
	

	

	
		
			
		
	

	

	
	 

	
	 

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		
		
		
			
				
				
					<a href="file:///C:/cgi/reprint/31/5/1024">
		<strong>Full Text</strong> (PDF)</a>


				
			
		
		</strong>
		</td></tr>
	
	

	
	
	
	
	

	
	
	

	
	




	
		

	
		

	
		
		

			


	

			

			
		
	

			
	  
	

			

			

			
	
	

	
		
	













	
	
	

	
		
	

	 

	
	
		  
    

	
	
	
	







		
	
		
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="file:///C:/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;saveAlert=no&amp;cited_by_criteria_resid=erj;31/5/1024&amp;return_type=article&amp;return_url=http%3A%2F%2Ferj.ersjournals.com%2Fcgi%2Fcontent%2Ffull%2F31%2F5%2F1024">
				Alert me when this article is cited</a></strong>
			</td></tr>
	

		
		

		
		

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="file:///C:/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;saveAlert=no&amp;correction_criteria_value=31/5/1024&amp;return_type=article&amp;return_url=http%3A%2F%2Ferj.ersjournals.com%2Fcgi%2Fcontent%2Ffull%2F31%2F5%2F1024">
				Alert me if a correction is posted</a></strong>
			</td></tr>
		
























			
		
			
			
			
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
					<strong><a rel="nofollow" href="file:///C:/cgi/citemap?id=erj;31/5/1024">
					Citation Map</a></strong>
				</td></tr>
		
	

			
			
<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " width="200" height="1" src="./674_files/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">Services</td></tr>

	

	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " width="200" height="1" src="./674_files/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="file:///C:/cgi/mailafriend?url=http%3A%2F%2Ferj.ersjournals.com%2Fcgi%2Fcontent%2Ffull%2F31%2F5%2F1024&amp;title=Heart-type+fatty+acid-binding+protein+for+risk+assessment+of+chronic+thromboembolic+pulmonary+hypertension">
				Email this article to a friend</a></strong>
			</td></tr>
			
			


	

	

	

		
		



			
			
			
		
	

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		<a href="file:///C:/cgi/search?qbe=erj;09031936.00100407&amp;journalcode=erj&amp;minscore=5000">
		Similar articles in this journal</a>
		</strong>
		</td></tr>

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="file:///C:/cgi/external_ref?access_num=18256058&amp;link_type=MED_NBRS">
				Similar articles in PubMed</a></strong>
			</td></tr>
		
	


		



			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="file:///C:/cgi/alerts/etoc">
				Alert me to new issues of the journal</a></strong>
			</td></tr>
		

		
		
	

		
		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
			<strong><a href="file:///C:/cgi/citmgr?gca=erj;31/5/1024">
			Download to citation manager</a></strong>
			</td></tr>
		
		
	


	
		
	

	



  			
		
		
		
	


	

	




	





		

		

	
	
	
		


	

	

	


	





	


	
		 
	

		
		
	















	
		
			
				
				
<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " width="200" height="1" src="./674_files/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">Google Scholar</td></tr>

	

	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " width="200" height="1" src="./674_files/spacer.gif"></td></tr>
						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://scholar.google.com/scholar?q=%22author%3AM.+author%3ALankeit%22">
							Articles by Lankeit, M.</a></strong>
						</td></tr>
				
				
			
				
			
				
			
				
			
				
			
				
			
				
			
				
			
				
			
				
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://scholar.google.com/scholar?q=%22author%3AI.%20M.+author%3ALang%22">
							Articles by Lang, I. M.</a></strong>
						</td></tr>
				
				
			
		
		
	
	
	
	

		
			
				
			
		
	










	





	
		
<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " width="200" height="1" src="./674_files/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">PubMed</td></tr>

	

	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " width="200" height="1" src="./674_files/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="file:///C:/cgi/external_ref?access_num=18256058&amp;link_type=PUBMED">
				PubMed Citation</a></strong>
			</td></tr>
		
	

	
		
		
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="file:///C:/cgi/external_ref?access_num=Lankeit+M&amp;link_type=AUTHORSEARCH">
							Articles by Lankeit, M.</a></strong>
						</td></tr>
				
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="file:///C:/cgi/external_ref?access_num=Lang+IM&amp;link_type=AUTHORSEARCH">
							Articles by Lang, I. M.</a></strong>
						</td></tr>
				
			
		

		
	

	
















	















	


































	
		

	

		
			
		
	 
		











	

	






































	</tbody></table>
</td></tr></tbody></table> 


		
	



 







 





	
	
	
	
	
	
    
	
	
	
	
		<font size="-1">
Eur Respir J 2008; 31:1024-1029<br>
Copyright ©<a href="file:///C:/misc/terms.shtml">ERS Journals Ltd</a> 2008
</font><br>
<h2>
Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension</h2>
<strong>
<nobr>M. Lankeit<sup>1</sup><sup>,4</sup></nobr>, 
<nobr>C. Dellas<sup>1</sup><sup>,4</sup></nobr>, 
<nobr>A. Panzenb&#246;ck<sup>2</sup></nobr>, 
<nobr>N. Skoro-Sajer<sup>2</sup></nobr>, 
<nobr>D. Bonderman<sup>2</sup></nobr>, 
<nobr>M. Olschewski<sup>3</sup></nobr>, 
<nobr>K. Sch&#228;fer<sup>1</sup></nobr>, 
<nobr>M. Puls<sup>1</sup></nobr>, 
<nobr>S. Konstantinides<sup>1</sup></nobr> and 
<nobr>I. M. Lang<sup>2</sup></nobr>
</strong><p>
<font size="-1">
<sup>1</sup> Dept of Cardiology and Pulmonology, University of Goettingen, Goettingen, <sup>3</sup> Dept of Medical Biometry and Statistics, University Hospital of Freiburg, Freiburg, Germany, <sup>2</sup> Dept of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Austria, <sup>4</sup> Both authors contributed equally.
</font></p><p>

<font size="-1">CORRESPONDENCE: S. Konstantinides, Dept of Cardiology and Pulmonology, University of Goettingen, D-37099 Goettingen, Germany. Fax: 49 5513914131. E-mail: <span id="em0"><a href="mailto:skonstan@med.uni-goettingen.de">skonstan@med.uni-goettingen.de</a></span><script type="text/javascript"><!--
 var u = "skonstan", d = "med.uni-goettingen.de"; document.getElementById("em0").innerHTML = '<a href="mailto:' + u + '@' + d + '">' + u + '@' + d + '<\/a>'//--></script></font></p><p>
<font size="-1">Keywords:&nbsp;Biomarkers, fatty acid-binding protein, prognosis, pulmonary hypertension</font></p><p>
<font size="-1">Received: August  3, 2007</font><br>

<font size="-1">Accepted January 15, 2008</font></p><p>

<a name="ABS"><!-- null --></a>
<br clear="right"><table width="100%" bgcolor="e1e1e1" cellpadding="0" cellspacing="0">
 <tbody><tr><td align="left" valign="middle" width="5%" bgcolor="ffffff"><img width="10" height="21" hspace="5" alt=" " src="./674_files/rarrow.gif"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
ABSTRACT
</font></th></tr></tbody></table>
<table align="right" cellpadding="5" border=""><tbody><tr><th align="left"><font size="-1">
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#top"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">TOP<br></a>
<img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/dot.gif"><font color="464c53">ABSTRACT</font><br>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC1"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">METHODS<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC2"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">RESULTS<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC3"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">DISCUSSION<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC4"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">Support statement<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC5"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">Statement of interest<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#BIBL"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">REFERENCES<br></a>
</font></th></tr></tbody></table>
&nbsp;<br>

<strong>
Heart-type fatty acid-binding protein (H-FABP) is a reliable<sup> </sup>marker of myocardial injury and was recently identified as a<sup> </sup>predictor of outcome in acute pulmonary embolism. The aim of<sup> </sup>the present study was to investigate the prognostic value of<sup> </sup>H-FABP in chronic thromboembolic pulmonary hypertension (CTEPH).<sup> </sup></strong></p><p><strong>

In total, 93 consecutive patients with CTEPH were studied. During<sup> </sup>long-term follow-up (median duration 1,260&nbsp;days, interquartile<sup> </sup>range (IQR) 708–2,460&nbsp;days), 46 (49%) patients had<sup> </sup>an adverse outcome, defined as CTEPH-related death, lung transplantation<sup> </sup>or persistent pulmonary hypertension after pulmonary endarterectomy<sup> </sup>(PEA).<sup> </sup></strong></p><p><strong>

Baseline H-FABP levels in plasma ranged from 0.69–24.3&nbsp;ng·mL<sup>–1</sup><sup> </sup>(median (IQR) 3.41 (2.28–4.86)&nbsp;ng·mL<sup>–1</sup>).<sup> </sup>Cox regression analysis revealed a hazard ratio of 1.10 (95%<sup> </sup>confidence interval 1.04–1.18) for each increase of H-FABP<sup> </sup>by 1&nbsp;ng·mL<sup>–1</sup>, and continuous elevations of<sup> </sup>H-FABP emerged as an independent predictor of adverse outcome<sup> </sup>by multivariable analysis. PEA was performed in 52 patients<sup> </sup>and favourably affected the long-term outcome. Kaplan–Meier<sup> </sup>analysis revealed that patients with baseline H-FABP concentrations<sup> </sup>&gt;2.7&nbsp;ng·mL<sup>–1</sup>, the median value of the biomarker<sup> </sup>in the surgically treated population, had a lower probability<sup> </sup>of event-free survival after PEA.<sup> </sup></strong></p><p><strong>

Heart-type fatty acid-binding protein is a promising novel biomarker<sup> </sup>for risk stratification of patients with chronic thromboembolic<sup> </sup>pulmonary hypertension.<sup> </sup></strong></p><p><strong>

</strong>

Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening<sup> </sup>condition which is increasingly being recognised as one of the<sup> </sup>leading causes of severe pulmonary hypertension (PH) <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R1">1</a>–<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R3">3</a>.<sup> </sup>Its pathogenesis is still poorly understood and its association<sup> </sup>with venous thromboembolism remains controversial. This is partly<sup> </sup>because the factors predisposing to these two syndromes are<sup> </sup>not identical, and up to 60% of patients with CTEPH deny previous<sup> </sup>symptoms of acute pulmonary embolism (PE) <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R4">4</a>, <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R5">5</a>. Nevertheless,<sup> </sup>it is generally believed that single or recurrent thromboembolic<sup> </sup>events in the lung may initiate an aberrant process of thrombus<sup> </sup>organisation, followed by progressive pulmonary vascular remodelling<sup> </sup>and obliteration. Early studies suggested that only 0.1–0.5%<sup> </sup>of patients who survive an acute episode of PE eventually present<sup> </sup>with CTEPH <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R5">5</a>, but more recent data indicate that the true proportion<sup> </sup>of patients developing this complication may be higher, ranging<sup> </sup>from 1–3.8% over a 2- to 4-yr period <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R6">6</a>, <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R7">7</a>. Viewed in the<sup> </sup>context of an annual PE incidence of <img src="./674_files/sim.gif" alt="~" border="0">50 cases per 100,000 population<sup> </sup><a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R8">8</a>, these rates highlight the disease burden imposed by CTEPH<sup> </sup>on patients and healthcare systems.<sup> </sup></p><p>

As in other forms of acute and chronic PH, the natural course<sup> </sup>and prognosis of CTEPH are largely determined by the progressive<sup> </sup>development of right ventricular dysfunction and failure. Baseline<sup> </sup>clinical and haemodynamic findings are of established value<sup> </sup>in severity assessment and identification of candidates for<sup> </sup>pulmonary endarterectomy (PEA) <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R1">1</a>. In addition, a number of studies<sup> </sup>on pulmonary arterial hypertension, three of which included<sup> </sup>a small subgroup of patients with CTEPH (five to 19 individuals)<sup> </sup><a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R9">9</a>–<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R11">11</a>, suggested that cardiac biomarkers such as troponin<sup> </sup>T and N-terminal pro brain natriuretic peptide (NT-proBNP) might<sup> </sup>be helpful tools for optimising risk stratification.<sup> </sup></p><p>

Heart-type fatty acid-binding protein (H-FABP) appears to offer<sup> </sup>a number of theoretical and practical advantages over cardiac<sup> </sup>troponins for the detection of myocardial injury <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R12">12</a>, <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R13">13</a>. Recently,<sup> </sup>Puls <i>et al</i>. <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R14">14</a> and Kaczy&#241;ska <i>et al</i>. <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R15">15</a> identified H-FABP<sup> </sup>as an early, highly sensitive and specific indicator of death<sup> </sup>or serious complications in acute PE. In the present study,<sup> </sup>the prognostic value of this biomarker was assessed in a large,<sup> </sup>single-centre population of 93 consecutive patients with CTEPH<sup> </sup>followed over a median period of <img src="./674_files/sim.gif" alt="~" border="0">3.5&nbsp;yrs. The results indicate<sup> </sup>that H-FABP is more sensitive than cardiac troponins in predicting<sup> </sup>an adverse outcome in this setting. Elevated H-FABP levels at<sup> </sup>diagnosis may help identify patients with a high risk of death,<sup> </sup>a need for lung transplantation or persistent PH after PEA,<sup> </sup>and their prognostic value appears to be independent of baseline<sup> </sup>haemodynamic parameters.<sup> </sup></p><p>

<a name="SEC1"><!-- null --></a>
<br clear="right"><table width="100%" bgcolor="e1e1e1" cellpadding="0" cellspacing="0">
 <tbody><tr><td align="left" valign="middle" width="5%" bgcolor="ffffff"><img width="10" height="21" hspace="5" alt=" " src="./674_files/rarrow.gif"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
METHODS
</font></th></tr></tbody></table>
<table align="right" cellpadding="5" border=""><tbody><tr><th align="left"><font size="-1">
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#top"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">TOP<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#ABS"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">ABSTRACT<br></a>
<img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/dot.gif"><font color="464c53">METHODS</font><br>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC2"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">RESULTS<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC3"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">DISCUSSION<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC4"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">Support statement<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC5"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">Statement of interest<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#BIBL"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">REFERENCES<br></a>
</font></th></tr></tbody></table>
&nbsp;<br>

<strong>Patient population and study design</strong><br>

Between September 1994 and November 2005, 93 consecutive patients<sup> </sup>were diagnosed with CTEPH, based on standardised criteria which<sup> </sup>included a mean pulmonary artery pressure (<i><img src="./674_files/Pmacr.gif" alt="P" border="0"></i><sub>pa</sub>) &gt;25&nbsp;mmHg<sup> </sup>at rest or &gt;30&nbsp;mmHg during exercise and a pulmonary<sup> </sup>vascular resistance (PVR) &gt;240&nbsp;dyn·s·cm<sup>–5</sup><sup> </sup><a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R16">16</a>. CTEPH was confirmed as the cause of pulmonary arterial hypertension<sup> </sup>using established diagnostic protocols and imaging techniques,<sup> </sup>including ventilation–perfusion lung scanning, computed<sup> </sup>tomographic angiography and selective pulmonary angiography<sup> </sup><a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R1">1</a>, <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R17">17</a>. Haemodynamic parameters were determined by right heart<sup> </sup>catheterisation in all cases. Cardiac index and PVR were calculated<sup> </sup>based on Fick measurements of pulmonary flow. Complete baseline<sup> </sup>evaluation was performed at the Medical University of Vienna<sup> </sup>(Vienna, Austria), which serves as a primary referral centre<sup> </sup>for patients in Austria with suspected PH and particularly CTEPH.<sup> </sup></p><p>

Treatment consisted of oral anticoagulants, aimed at maintaining<sup> </sup>an international normalised ratio of 2.0–3.0, as well<sup> </sup>as diuretics, digitalis and oxygen at the physician’s<sup> </sup>discretion. In addition, 52 patients (56% of the study population)<sup> </sup>underwent surgical PEA at various times during the follow-up<sup> </sup>period. The indications for PEA at the Medical University of<sup> </sup>Vienna have been described previously <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R18">18</a>. Briefly, patients<sup> </sup>were referred for PEA if they had a resting PVR &gt;300&nbsp;dyn·s·cm<sup>–5</sup><sup> </sup>(except for those with unilateral disease) and surgical accessibility<sup> </sup>of thromboembolic lesions. Surgery was not performed if PVR<sup> </sup>exceeded 1,100&nbsp;dyn·s·cm<sup>–5</sup> or if the<sup> </sup>patient had severe comorbidity or refused surgical treatment<sup> </sup><a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R18">18</a>.<sup> </sup></p><p>

An adverse outcome was defined as at least one of the following<sup> </sup>events during the follow-up period: 1) CTEPH-related death;<sup> </sup>2) need for lung transplantation; 3) persistent PH (as defined<sup> </sup>previously) despite PEA.<sup> </sup></p><p>

<strong>Biomarker testing</strong><br>

Venous plasma samples were collected at the time of initial<sup> </sup>diagnostic evaluation and at various times during the follow-up<sup> </sup>period. Samples were immediately stored at -80°C and later<sup> </sup>analysed in batches after a single thaw.<sup> </sup></p><p>

Plasma levels of H-FABP (dilution 1:5) were measured by a solid-phase<sup> </sup>sandwich ELISA (HyCult Biotechnology, Uden, the Netherlands)<sup> </sup>as described previously <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R14">14</a>. The calibrators of the assay covered<sup> </sup>the range 0–25&nbsp;ng·mL<sup>–1</sup>. The minimum<sup> </sup>detection level was 0.25&nbsp;ng·mL<sup>–1</sup> and the assay<sup> </sup>was linear within the range 0.1–25&nbsp;ng·mL<sup>–1</sup>.<sup> </sup>Cardiac troponin T levels were determined using a quantitative<sup> </sup>electrochemiluminescence immunoassay (Elecsys 1010/2010 analyser;<sup> </sup>Roche Diagnostics, Mannheim, Germany) with a minimal detection<sup> </sup>limit of 0.01&nbsp;ng·mL<sup>–1</sup>.<sup> </sup></p><p>

The investigator who determined the biomarker levels was unaware<sup> </sup>of the patients’ baseline parameters or clinical course.<sup> </sup>Biomarker levels were not used to guide patient management or<sup> </sup>monitor the effects of treatment during the initial hospital<sup> </sup>stay or at any time during the follow-up period. The study protocol<sup> </sup>was approved by the Ethics Committee of the Medical University<sup> </sup>of Vienna, and all patients gave informed consent.<sup> </sup></p><p>

<strong>Statistical analysis</strong><br>

The modified Kolmogorov–Smirnov test (Lilliefors test)<sup> </sup>was used to test for normal distribution of continuous variables.<sup> </sup>Continuous variables are expressed as medians with the corresponding<sup> </sup>interquartile range (IQR), and were compared using the Mann–Whitney<sup> </sup>U-test. Categorical variables were compared using Fisher’s<sup> </sup>exact test. Spearman rank correlation was used to identify baseline<sup> </sup>variables related to the levels of H-FABP. The prognostic relevance<sup> </sup>of H-FABP and other baseline parameters with respect to adverse<sup> </sup>long-term outcome, as defined previously, was estimated using<sup> </sup>Cox’s proportional hazards model, which considered continuous<sup> </sup>elevation of H-FABP levels and the haemodynamic variables. The<sup> </sup>results are presented as hazard ratios (HR) with corresponding<sup> </sup>95% confidence intervals (CI), and were compared by Wald’s<sup> </sup>test. The calculated HR and 95% CI values refer to: H-FABP increases<sup> </sup>of 1&nbsp;ng·mL<sup>–1</sup>; <i><img src="./674_files/Pmacr.gif" alt="P" border="0"></i><sub>pa</sub>, mean right atrial pressure<sup> </sup>(mRAP) and pulmonary capillary wedge pressure (PCWP) increases<sup> </sup>of 1&nbsp;mmHg; cardiac output (CO) increases of 1&nbsp;L·min<sup>–1</sup>;<sup> </sup>and PVR increases of 1&nbsp;dyn·s·cm<sup>–5</sup>.<sup> </sup>For the multivariable analysis, H-FABP and the univariable significant<sup> </sup>variables were entered into the Cox model simultaneously. Of<sup> </sup>note, cardiac troponin T was not considered in this model, since<sup> </sup>only four of the study patients had detectable levels at the<sup> </sup>time of diagnosis. In addition, event-free survival rates for<sup> </sup>the type of treatment (PEA <i>versus</i> conservative) and for tertiles<sup> </sup>of H-FABP were estimated by the method of Kaplan–Meier<sup> </sup>and compared with the log-rank test. All tests were two-sided<sup> </sup>and used a significance level of 0.05.<sup> </sup></p><p>

<a name="SEC2"><!-- null --></a>
<br clear="right"><table width="100%" bgcolor="e1e1e1" cellpadding="0" cellspacing="0">
 <tbody><tr><td align="left" valign="middle" width="5%" bgcolor="ffffff"><img width="10" height="21" hspace="5" alt=" " src="./674_files/rarrow.gif"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
RESULTS
</font></th></tr></tbody></table>
<table align="right" cellpadding="5" border=""><tbody><tr><th align="left"><font size="-1">
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#top"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">TOP<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#ABS"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">ABSTRACT<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC1"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">METHODS<br></a>
<img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/dot.gif"><font color="464c53">RESULTS</font><br>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC3"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">DISCUSSION<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC4"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">Support statement<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC5"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">Statement of interest<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#BIBL"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">REFERENCES<br></a>
</font></th></tr></tbody></table>
&nbsp;<br>

<strong>Clinical and haemodynamic predictors of an adverse outcome of CTEPH</strong><br>

The baseline clinical and haemodynamic findings of the study<sup> </sup>patients are shown in table&nbsp;1<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#T1"><img border="1" width="8" height="7" alt="Go" src="./674_files/fig-down.gif"></a>. During the follow-up period,<sup> </sup>which ranged between 8&nbsp;days and 13&nbsp;yrs (median (IQR)<sup> </sup>1,260 (708–2,460)&nbsp;days), 46 (49%) patients had an<sup> </sup>adverse outcome. Of these, 33 patients died of CTEPH-related<sup> </sup>causes, five patients underwent lung transplantation (two of<sup> </sup>whom died of CTEPH-related causes during follow-up), and eight<sup> </sup>patients had persistent PH despite surgical treatment (PEA).<sup> </sup>In agreement with previous reports <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R19">19</a>, <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R20">20</a>, patients with an<sup> </sup>adverse outcome had a significantly shorter 6-min walking distance<sup> </sup>at baseline. They also had higher <i><img src="./674_files/Pmacr.gif" alt="P" border="0"></i><sub>pa</sub>, mRAP and PVR, and a lower<sup> </sup>CO at initial right heart catheterisation (table&nbsp;1<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#T1"><img border="1" width="8" height="7" alt="Go" src="./674_files/fig-down.gif"></a>). Accordingly,<sup> </sup>these haemodynamic variables were associated with an increased<sup> </sup>risk of an adverse long-term outcome by univariable Cox regression<sup> </sup>analysis (table&nbsp;2<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#T2"><img border="1" width="8" height="7" alt="Go" src="./674_files/fig-down.gif"></a>).<sup> </sup></p><p>

<a name="T1"><!-- null --></a>
<br clear="all"></p><center><table width="95%" cellpadding="0" cellspacing="0"><tbody><tr bgcolor="e1e1e1"><td><table cellpadding="2" cellspacing="2">
<tbody><tr bgcolor="e1e1e1"><td align="center" valign="top" bgcolor="ffffff">
<strong>View this table:</strong><br>
<nobr><a href="file:///C:/cgi/content/full/31/5/1024/T1">[in this window]</a><br>
<a href="file:///C:/cgi/content-nw/full/31/5/1024/T1" onclick="startTarget(&#39;T1&#39;, 500, 400); this.href=&#39;/cgi/content-nw/full/31/5/1024/T1&#39;" onmouseover="window.status=&#39;View figure in a separate window&#39;; return true" target="T1">[in a new window]</a><br>
<br>&nbsp;</nobr>
</td><td align="left" valign="top">
Table 1— Baseline characteristics of 93 patients with chronic thromboembolic pulmonary hypertension(CTEPH)<p>


</p></td></tr></tbody></table>
</td></tr></tbody></table></center>&nbsp;<br>


<a name="T2"><!-- null --></a>
<br clear="all"><center><table width="95%" cellpadding="0" cellspacing="0"><tbody><tr bgcolor="e1e1e1"><td><table cellpadding="2" cellspacing="2">
<tbody><tr bgcolor="e1e1e1"><td align="center" valign="top" bgcolor="ffffff">
<strong>View this table:</strong><br>
<nobr><a href="file:///C:/cgi/content/full/31/5/1024/T2">[in this window]</a><br>
<a href="file:///C:/cgi/content-nw/full/31/5/1024/T2" onclick="startTarget(&#39;T2&#39;, 500, 400); this.href=&#39;/cgi/content-nw/full/31/5/1024/T2&#39;" onmouseover="window.status=&#39;View figure in a separate window&#39;; return true" target="T2">[in a new window]</a><br>
<br>&nbsp;</nobr>
</td><td align="left" valign="top">
Table 2— Baseline heart-type fatty acid-binding protein (H-FABP) plasma levels and haemodynamic parameters as predictors of adverse outcome in chronic thromboembolic pulmonary hypertension<p>


</p></td></tr></tbody></table>
</td></tr></tbody></table></center>&nbsp;<br>


<strong>Prognostic relevance of H-FABP concentrations at diagnosis</strong><br>

At the time of initial diagnostic evaluation, H-FABP levels<sup> </sup>in plasma ranged from 0.69–24.3&nbsp;ng·mL<sup>–1</sup><sup> </sup>(median (IQR) 3.41 (2.28–4.86)&nbsp;ng·mL<sup>–1</sup>),<sup> </sup>and were weakly correlated with CO (r =  -0.21, p = 0.045),<sup> </sup>mRAP (r = 0.21, p = 0.044), PCWP (r = 0.29, p = 0.006) and the<sup> </sup>6-min walking distance (r =  -0.43, p = 0.003). Baseline H-FABP<sup> </sup>concentrations were significantly higher in patients with an<sup> </sup>adverse outcome during follow-up compared with those with a<sup> </sup>favourable course (3.64 (2.86–5.37) <i>versus</i> 2.96 (2.16–4.49)&nbsp;ng·mL<sup>–1</sup>,<sup> </sup>respectively; p = 0.028). Univariable Cox regression analysis<sup> </sup>revealed an HR (95% CI) of 1.10 (1.04–1.18) for each increase<sup> </sup>of H-FABP by 1&nbsp;ng·mL<sup>–1</sup> (p = 0.002; table&nbsp;2<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#T2"><img border="1" width="8" height="7" alt="Go" src="./674_files/fig-up.gif"></a>).<sup> </sup>Importantly, H-FABP emerged as an independent predictor of outcome<sup> </sup>by multivariable analysis that included baseline haemodynamic<sup> </sup>parameters and the type of treatment (table&nbsp;2<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#T2"><img border="1" width="8" height="7" alt="Go" src="./674_files/fig-up.gif"></a>). Kaplan–Meier<sup> </sup>analysis (fig.&nbsp;1<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#F1"><img border="1" width="8" height="7" alt="Go" src="./674_files/fig-down.gif"></a>) further supported the prognostic importance<sup> </sup>of the biomarker by showing that patients with H-FABP levels<sup> </sup>in the lowest tertile (&lt;2.7&nbsp;ng·mL<sup>–1</sup>) had<sup> </sup>a probability of event-free survival which was significantly<sup> </sup>higher than that of patients in the middle tertile (2.7–4.4&nbsp;ng·mL<sup>–1</sup>;<sup> </sup>p = 0.031 by log-rank test) or the highest tertile (&gt;4.4&nbsp;ng·mL<sup>–1</sup>;<sup> </sup>p = 0.004).<sup> </sup><p>

<a name="F1"><!-- null --></a>
<br clear="all"></p><center><table width="95%" cellpadding="0" cellspacing="0"><tbody><tr bgcolor="e1e1e1"><td><table cellpadding="2" cellspacing="2">
<tbody><tr bgcolor="e1e1e1"><td align="center" valign="top" bgcolor="ffffff">
<a href="file:///C:/cgi/content/full/31/5/1024/F1"><img hspace="10" vspace="5" border="2" width="200" height="140" src="./674_files/1024fig1.gif" alt="Figure 1"></a><br>

<strong>View larger version</strong> (11K):<br>
<nobr><a href="file:///C:/cgi/content/full/31/5/1024/F1">[in this window]</a><br>
<a href="file:///C:/cgi/content-nw/full/31/5/1024/F1" onclick="startTarget(&#39;F1&#39;, 590, 507); this.href=&#39;/cgi/content-nw/full/31/5/1024/F1&#39;" onmouseover="window.status=&#39;View figure in a separate window&#39;; return true" target="F1">[in a new window]</a><br>
<br>&nbsp;</nobr>
</td><td align="left" valign="top">
Fig. 1— Elevated heart-type fatty acid-binding protein (H-FABP) levels were associated with a higher likelihood of an adverse outcome in patients with chronic thromboembolic pulmonary hypertension. Kaplan–Meier curves showing probability of event-free survival according to the tertiles of H-FABP levels at initial diagnostic evaluation. ––––: H-FABP &lt;2.7&nbsp;ng·mL<sup>–1</sup>; ······: H-FABP 2.7–4.4&nbsp;ng·mL<sup>–1</sup>; ------: H-FABP &gt;4.4&nbsp;ng·mL<sup>–1</sup>. Difference between the lowest and the middle tertile, p = 0.031 (log-rank); difference between the middle and the highest tertile, p = 0.004.<p>


</p></td></tr></tbody></table>
</td></tr></tbody></table></center>&nbsp;<br>


Surgical PEA has been reported to improve the prognosis of patients<sup> </sup>with CTEPH <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R21">21</a>. In the present study, 52 patients who underwent<sup> </sup>PEA had a significantly higher probability of event-free survival<sup> </sup>during follow-up compared with those who were treated medically<sup> </sup>(p = 0.002 by log-rank; fig.&nbsp;2<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#F2"><img border="1" width="8" height="7" alt="Go" src="./674_files/fig-down.gif"></a>). Univariable and multivariable<sup> </sup>analysis using the Cox model both confirmed that surgical treatment<sup> </sup>of CTEPH was associated with a significantly lower risk of an<sup> </sup>adverse outcome (table&nbsp;2<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#T2"><img border="1" width="8" height="7" alt="Go" src="./674_files/fig-up.gif"></a>). Importantly, of the patients<sup> </sup>who underwent surgical treatment of CTEPH, those with an adverse<sup> </sup>long-term outcome had significantly higher baseline levels of<sup> </sup>H-FABP compared with those with a favourable outcome (median<sup> </sup>(IQR) 3.55 (2.11–5.63)&nbsp;ng·mL<sup>–1</sup>, n =<sup> </sup>22, <i>versus</i> 2.29 (1.68–3.49)&nbsp;ng·mL<sup>–1</sup>,<sup> </sup>n = 30, respectively; p = 0.026). In agreement with this observation,<sup> </sup>Kaplan–Meier analysis showed a lower probability of event-free<sup> </sup>survival after PEA in patients with H-FABP concentrations &gt;2.7&nbsp;ng·mL<sup>–1</sup><sup> </sup>(the median value of this biomarker in the surgically treated<sup> </sup>population) at diagnosis (p = 0.002 by log-rank; fig.&nbsp;3<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#F3"><img border="1" width="8" height="7" alt="Go" src="./674_files/fig-down.gif"></a>).<sup> </sup><p>

<a name="F2"><!-- null --></a>
<br clear="all"></p><center><table width="95%" cellpadding="0" cellspacing="0"><tbody><tr bgcolor="e1e1e1"><td><table cellpadding="2" cellspacing="2">
<tbody><tr bgcolor="e1e1e1"><td align="center" valign="top" bgcolor="ffffff">
<a href="file:///C:/cgi/content/full/31/5/1024/F2"><img hspace="10" vspace="5" border="2" width="200" height="140" src="./674_files/1024fig2.gif" alt="Figure 2"></a><br>

<strong>View larger version</strong> (11K):<br>
<nobr><a href="file:///C:/cgi/content/full/31/5/1024/F2">[in this window]</a><br>
<a href="file:///C:/cgi/content-nw/full/31/5/1024/F2" onclick="startTarget(&#39;F2&#39;, 590, 507); this.href=&#39;/cgi/content-nw/full/31/5/1024/F2&#39;" onmouseover="window.status=&#39;View figure in a separate window&#39;; return true" target="F2">[in a new window]</a><br>
<br>&nbsp;</nobr>
</td><td align="left" valign="top">
Fig. 2— Kaplan–Meier curves showing probability of event-free survival for 52 patients who underwent pulmonary endarterectomy (PEA; ––––) compared with 41 patients who received medical treatment (no PEA; ······). p = 0.002 by log-rank.<p>


</p></td></tr></tbody></table>
</td></tr></tbody></table></center>&nbsp;<br>


<a name="F3"><!-- null --></a>
<br clear="all"><center><table width="95%" cellpadding="0" cellspacing="0"><tbody><tr bgcolor="e1e1e1"><td><table cellpadding="2" cellspacing="2">
<tbody><tr bgcolor="e1e1e1"><td align="center" valign="top" bgcolor="ffffff">
<a href="file:///C:/cgi/content/full/31/5/1024/F3"><img hspace="10" vspace="5" border="2" width="200" height="139" src="./674_files/1024fig3.gif" alt="Figure 3"></a><br>

<strong>View larger version</strong> (10K):<br>
<nobr><a href="file:///C:/cgi/content/full/31/5/1024/F3">[in this window]</a><br>
<a href="file:///C:/cgi/content-nw/full/31/5/1024/F3" onclick="startTarget(&#39;F3&#39;, 590, 506); this.href=&#39;/cgi/content-nw/full/31/5/1024/F3&#39;" onmouseover="window.status=&#39;View figure in a separate window&#39;; return true" target="F3">[in a new window]</a><br>
<br>&nbsp;</nobr>
</td><td align="left" valign="top">
Fig. 3— Elevated heart-type fatty acid-binding protein (H-FABP) levels were associated with a higher likelihood of an adverse outcome in patients with chronic thromboembolic pulmonary hypertension undergoing pulmonary endarterectomy. Kaplan–Meier curves showing probability of event-free survival in 52 operated patients according to dichotomised baseline H-FABP levels, <i>i.e.</i> below (––––) or above (·······) the calculated median value in this population (2.7&nbsp;ng·mL<sup>–1</sup>); p = 0.002 by log-rank.<p>


</p></td></tr></tbody></table>
</td></tr></tbody></table></center>&nbsp;<br>


In contrast to a previous study in patients with pulmonary arterial<sup> </sup>hypertension of various aetiologies <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R11">11</a>, only four (4.3%) of<sup> </sup>the patients with CTEPH in the present study had detectable<sup> </sup>cardiac troponin T concentrations at diagnosis. All of these<sup> </sup>patients had an adverse outcome at follow-up.<sup> </sup><p>

<a name="SEC3"><!-- null --></a>
<br clear="right"><table width="100%" bgcolor="e1e1e1" cellpadding="0" cellspacing="0">
 <tbody><tr><td align="left" valign="middle" width="5%" bgcolor="ffffff"><img width="10" height="21" hspace="5" alt=" " src="./674_files/rarrow.gif"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
DISCUSSION
</font></th></tr></tbody></table>
<table align="right" cellpadding="5" border=""><tbody><tr><th align="left"><font size="-1">
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#top"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">TOP<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#ABS"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">ABSTRACT<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC1"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">METHODS<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC2"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">RESULTS<br></a>
<img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/dot.gif"><font color="464c53">DISCUSSION</font><br>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC4"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">Support statement<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC5"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">Statement of interest<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#BIBL"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">REFERENCES<br></a>
</font></th></tr></tbody></table>
&nbsp;<br>

Currently available biomarkers of myocardial injury, particularly<sup> </sup>the cardiac troponins I and T, are widely used in the triage<sup> </sup>of patients with acute coronary syndromes <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R22">22</a>, <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R23">23</a>. Interestingly,<sup> </sup>cardiac troponin levels are also elevated in acute cor pulmonale<sup> </sup>resulting from PE <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R24">24</a>, but it is unknown whether they can be<sup> </sup>used to detect right ventricular myocardial injury in the setting<sup> </sup>of chronic recurrent venous thromboembolic disease and CTEPH.<sup> </sup>Evidence has begun to accumulate that patients with pulmonary<sup> </sup>arterial hypertension may exhibit prognostically relevant elevations<sup> </sup>of cardiac troponin or brain natriuretic peptide (BNP) levels<sup> </sup>in the circulation <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R9">9</a>–<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R11">11</a>, <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R25">25</a>, <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R26">26</a>, but these studies included<sup> </sup>very few, if any, patients with CTEPH.<sup> </sup></p><p>

The present study focused on a population of 93 patients with<sup> </sup>CTEPH who were followed over a median period of 3.5&nbsp;yrs;<sup> </sup>during this time, 52 (56%) patients underwent surgical treatment<sup> </sup>(PEA) and 46 (49%) patients had an adverse outcome defined as<sup> </sup>death of CTEPH-related causes, need for lung transplantation<sup> </sup>or persistent PH despite PEA. The present authors assessed the<sup> </sup>prognostic value of H-FABP, a novel, highly sensitive and specific<sup> </sup>biomarker of myocardial injury, which has yielded promising<sup> </sup>results in patients with acute coronary syndromes <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R12">12</a>, <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R27">27</a> and,<sup> </sup>recently, in the setting of acute PE <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R14">14</a>, <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R15">15</a>. In the present<sup> </sup>study population with CTEPH, baseline H-FABP concentrations<sup> </sup>were significantly higher in patients with an adverse outcome<sup> </sup>during the follow-up period compared with those with a favourable<sup> </sup>course, and the probability of event-free survival progressively<sup> </sup>declined with increasing levels (tertiles) of H-FABP in plasma.<sup> </sup>By Cox regression analysis, H-FABP levels, as well as mRAP and<sup> </sup>surgical treatment, emerged as independent predictors of an<sup> </sup>adverse outcome.<sup> </sup></p><p>

In contrast to H-FABP, the present authors found a disappointingly<sup> </sup>low prognostic sensitivity of cardiac troponin T in the patient<sup> </sup>population, as only four (4%) patients had detectable troponin<sup> </sup>levels at baseline. All of these patients had an adverse outcome<sup> </sup>at follow-up; thus, cardiac troponin elevation appears, when<sup> </sup>present, to be an ominous prognostic indicator in CTEPH. Nevertheless,<sup> </sup>the present results partly contradict a previous report, which<sup> </sup>found this biomarker to be more frequently elevated in pulmonary<sup> </sup>arterial hypertension of various aetiologies <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R11">11</a>. Although the<sup> </sup>exact reasons for the apparent discrepancy are unclear, the<sup> </sup>earlier study included only a small number of patients with<sup> </sup>CTEPH. The findings of the present study indicate a superiority<sup> </sup>of H-FABP over troponin T in risk stratification of CTEPH and<sup> </sup>in the prediction of long-term event-free survival. These results<sup> </sup>are consistent with the recently reviewed theoretical advantages<sup> </sup>of H-FABP <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R12">12</a>–<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R14">14</a> including, for example, its small molecular<sup> </sup>size and favourable kinetics, its myocardial specificity which<sup> </sup>resembles that of the MB isoenzyme of creatine kinase, and its<sup> </sup>confinement to the cytoplasmic space.<sup> </sup></p><p>

The present study did not compare the prognostic value of H-FABP<sup> </sup>to that of the natriuretic peptides BNP and NT-proBNP. Circulating<sup> </sup>levels of these latter biomarkers have been shown to correlate<sup> </sup>with the prognosis of patients with various forms of pulmonary<sup> </sup>arterial hypertension <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R9">9</a>–<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R11">11</a>, <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R25">25</a>, <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R26">26</a>. At present, the available<sup> </sup>evidence suggests that natriuretic peptides could be useful<sup> </sup>for monitoring the clinical course of patients with pulmonary<sup> </sup>arterial hypertension, and the effects of therapy <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R16">16</a>, but the<sup> </sup>wide variations in the reported cut-off values for the assessment<sup> </sup>of cor pulmonale pose practical limitations to their routine<sup> </sup>use <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R28">28</a>.<sup> </sup></p><p>

PEA is currently the treatment of choice for selected patients<sup> </sup>with CTEPH <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R29">29</a>. At present, the patient’s functional status,<sup> </sup>together with invasively obtained haemodynamic parameters, is<sup> </sup>used to assess operability and guide therapeutic decisions <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R1">1</a>,<sup> </sup><a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R21">21</a>, <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R29">29</a>. In the present study, the independent favourable influence<sup> </sup>of PEA on the long-term outcome of patients with CTEPH was confirmed.<sup> </sup>Importantly, of the 52 patients who underwent surgical treatment<sup> </sup>of CTEPH, those with an adverse long-term outcome had significantly<sup> </sup>higher baseline levels of H-FABP compared with those with a<sup> </sup>favourable outcome. These findings suggest that H-FABP measurements<sup> </sup>may help identify patients who could benefit most from surgical<sup> </sup>treatment. This clinically relevant hypothesis needs to be tested<sup> </sup>by larger, preferably prospective management, studies. In addition,<sup> </sup>further adequately powered studies are needed to determine whether<sup> </sup>serial measurements of H-FABP can be used as a surrogate marker<sup> </sup>for monitoring the response to surgical or medical therapy.<sup> </sup>In this regard, it also needs to be mentioned that the present<sup> </sup>study did not include patients treated with novel pharmacological<sup> </sup>agents, such as prostacyclin analogues, endothelin receptor<sup> </sup>antagonists and phosphodiesterase-5 inhibitors. Preliminary<sup> </sup>reports suggest that these drugs may favourably affect the clinical<sup> </sup>course of CTEPH <a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#R30">30</a>.<sup> </sup></p><p>

In conclusion, the results of the present study indicate that<sup> </sup>heart-type fatty acid-binding protein is a reliable novel predictor<sup> </sup>of long-term outcome and, thus, a useful tool for risk stratification<sup> </sup>of patients with chronic thromboembolic pulmonary hypertension,<sup> </sup>including those undergoing pulmonary endarterectomy. The present<sup> </sup>findings provide the rationale for further studies to define<sup> </sup>the exact place of cardiac biomarkers and particularly heart-type<sup> </sup>fatty acid-binding protein, along with, or as an alternative<sup> </sup>to, haemodynamic parameters in management algorithms for this<sup> </sup>life-threatening disorder, which appears to affect more patients<sup> </sup>than previously thought.<sup> </sup></p><p>

<sup> </sup></p><p>

<a name="SEC4"><!-- null --></a>
<br clear="right"><table width="100%" bgcolor="e1e1e1" cellpadding="0" cellspacing="0">
 <tbody><tr><td align="left" valign="middle" width="5%" bgcolor="ffffff"><img width="10" height="21" hspace="5" alt=" " src="./674_files/rarrow.gif"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
Support statement
</font></th></tr></tbody></table>
<table align="right" cellpadding="5" border=""><tbody><tr><th align="left"><font size="-1">
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#top"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">TOP<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#ABS"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">ABSTRACT<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC1"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">METHODS<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC2"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">RESULTS<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC3"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">DISCUSSION<br></a>
<img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/dot.gif"><font color="464c53">Support statement</font><br>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC5"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">Statement of interest<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#BIBL"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">REFERENCES<br></a>
</font></th></tr></tbody></table>
&nbsp;<br>

I.M. Lang was supported by grant No. S9406-B11 from the Fonds<sup> </sup>zur F&#246;rderung der wissenschaftlichen Forschung (FWF), Vienna,<sup> </sup>Austria.<sup> </sup></p><p>

<a name="SEC5"><!-- null --></a>
<br clear="right"><table width="100%" bgcolor="e1e1e1" cellpadding="0" cellspacing="0">
 <tbody><tr><td align="left" valign="middle" width="5%" bgcolor="ffffff"><img width="10" height="21" hspace="5" alt=" " src="./674_files/rarrow.gif"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
Statement of interest
</font></th></tr></tbody></table>
<table align="right" cellpadding="5" border=""><tbody><tr><th align="left"><font size="-1">
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#top"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">TOP<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#ABS"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">ABSTRACT<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC1"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">METHODS<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC2"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">RESULTS<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC3"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">DISCUSSION<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC4"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">Support statement<br></a>
<img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/dot.gif"><font color="464c53">Statement of interest</font><br>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#BIBL"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/darrow.gif">REFERENCES<br></a>
</font></th></tr></tbody></table>
&nbsp;<br>

None declared.<sup> </sup></p><p>

<sup> </sup></p><p>



<a name="FN"><!-- null --></a>
<br clear="right"><table width="100%" bgcolor="e1e1e1" cellpadding="0" cellspacing="0">
 <tbody><tr><td align="left" valign="middle" width="5%" bgcolor="ffffff"><img width="10" height="21" hspace="5" alt=" " src="./674_files/rarrow.gif"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
FOOTNOTES
</font></th></tr></tbody></table>
&nbsp;<br>

<a name=""><!-- null --></a>
<b>For editorial comments see page 915.</b><sup> </sup></p><p>



<a name="BIBL"><!-- null --></a>
<br clear="right"><table width="100%" bgcolor="e1e1e1" cellpadding="0" cellspacing="0">
 <tbody><tr><td align="left" valign="middle" width="5%" bgcolor="ffffff"><img width="10" height="21" hspace="5" alt=" " src="./674_files/rarrow.gif"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
REFERENCES
</font></th></tr></tbody></table>
<table align="right" cellpadding="5" border=""><tbody><tr><th align="left"><font size="-1">
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#top"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">TOP<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#ABS"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">ABSTRACT<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC1"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">METHODS<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC2"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">RESULTS<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC3"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">DISCUSSION<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC4"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">Support statement<br></a>
<a href="file:///C:/Users/Admin/AppData/Local/Temp/THROMB~1.HTM#SEC5"><img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/uarrow.gif">Statement of interest<br></a>
<img width="11" height="9" border="0" hspace="5" alt=" " src="./674_files/dot.gif"><font color="464c53">REFERENCES</font><br>
</font></th></tr></tbody></table>
&nbsp;<br>

</p><ol compact="">
<a name="R1"><!-- null --></a><li value="1"> Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. <em>Circulation</em> 2006;113:2011–2020.<!-- HIGHWIRE ID="31:5:1024:1" --><a href="file:///C:/cgi/ijlink?linkType=FULL&amp;journalCode=circulationaha&amp;resid=113/16/2011"><nobr>[<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R2"><!-- null --></a></li><li value="2"> Lang IM. Chronic thromboembolic pulmonary hypertension–not so rare after all. <em>N Engl J Med</em> 2004;350:2236–2238.<!-- HIGHWIRE ID="31:5:1024:2" --><a href="file:///C:/cgi/ijlink?linkType=FULL&amp;journalCode=nejm&amp;resid=350/22/2236"><nobr>[<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R3"><!-- null --></a></li><li value="3"> Simonneau G, Gali&#232; N, Rubin LJ, <i>et al.</i> Clinical classification of pulmonary hypertension. <em>J Am Coll Cardiol</em> 2004;43: Suppl. 12 5S–12S.<!-- HIGHWIRE ID="31:5:1024:3" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=jacc&amp;resid=43/12_Suppl_S/5S"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R4"><!-- null --></a></li><li value="4"> Lang I, Kerr K. Risk factors for chronic thromboembolic pulmonary hypertension. <em>Proc Am Thorac Soc</em> 2006;3:568–570.<!-- HIGHWIRE ID="31:5:1024:4" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=procats&amp;resid=3/7/568"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R5"><!-- null --></a></li><li value="5"> Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. <em>Proc Am Thorac Soc</em> 2006;3:564–567.<!-- HIGHWIRE ID="31:5:1024:5" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=procats&amp;resid=3/7/564"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R6"><!-- null --></a></li><li value="6"> Becattini C, Agnelli G, Pesavento R, <i>et al.</i> Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. <em>Chest</em> 2006;130:172–175.<!-- HIGHWIRE ID="31:5:1024:6" --><a href="file:///C:/cgi/external_ref?access_num=10.1378/chest.130.1.172&amp;link_type=DOI">[CrossRef]</a><a href="file:///C:/cgi/external_ref?access_num=000239219300028&amp;link_type=ISI">[ISI]</a><a href="file:///C:/cgi/external_ref?access_num=16840398&amp;link_type=MED">[Medline]</a>
<a href="file:///C:/cgi/external_ref?access_num=16840398&amp;displayid=142677&amp;link_type=INFOTRIEVE">[Order article via Infotrieve]</a><!-- /HIGHWIRE --><a name="R7"><!-- null --></a></li><li value="7"> Pengo V, Lensing AW, Prins MH, <i>et al.</i> Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. <em>N Engl J Med</em> 2004;350:2257–2264.<!-- HIGHWIRE ID="31:5:1024:7" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=nejm&amp;resid=350/22/2257"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R8"><!-- null --></a></li><li value="8"> Stein PD, Kayali F, Olson RE. Regional differences in rates of diagnosis and mortality of pulmonary thromboembolism. <em>Am J Cardiol</em> 2004;93:1194–1197.<!-- HIGHWIRE ID="31:5:1024:8" --><a href="file:///C:/cgi/external_ref?access_num=10.1016/j.amjcard.2004.01.061&amp;link_type=DOI">[CrossRef]</a><a href="file:///C:/cgi/external_ref?access_num=000221140100030&amp;link_type=ISI">[ISI]</a><a href="file:///C:/cgi/external_ref?access_num=15110225&amp;link_type=MED">[Medline]</a>
<a href="file:///C:/cgi/external_ref?access_num=15110225&amp;displayid=142677&amp;link_type=INFOTRIEVE">[Order article via Infotrieve]</a><!-- /HIGHWIRE --><a name="R9"><!-- null --></a></li><li value="9"> Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. <em>Am J Cardiol</em> 2006;98:525–529.<!-- HIGHWIRE ID="31:5:1024:9" --><a href="file:///C:/cgi/external_ref?access_num=10.1016/j.amjcard.2006.02.061&amp;link_type=DOI">[CrossRef]</a><a href="file:///C:/cgi/external_ref?access_num=000240039500019&amp;link_type=ISI">[ISI]</a><a href="file:///C:/cgi/external_ref?access_num=16893710&amp;link_type=MED">[Medline]</a>
<a href="file:///C:/cgi/external_ref?access_num=16893710&amp;displayid=142677&amp;link_type=INFOTRIEVE">[Order article via Infotrieve]</a><!-- /HIGHWIRE --><a name="R10"><!-- null --></a></li><li value="10"> Fijalkowska A, Kurzyna M, Torbicki A, <i>et al.</i> Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. <em>Chest</em> 2006;129:1313–1321.<!-- HIGHWIRE ID="31:5:1024:10" --><a href="file:///C:/cgi/external_ref?access_num=10.1378/chest.129.5.1313&amp;link_type=DOI">[CrossRef]</a><a href="file:///C:/cgi/external_ref?access_num=000237618400029&amp;link_type=ISI">[ISI]</a><a href="file:///C:/cgi/external_ref?access_num=16685024&amp;link_type=MED">[Medline]</a>
<a href="file:///C:/cgi/external_ref?access_num=16685024&amp;displayid=142677&amp;link_type=INFOTRIEVE">[Order article via Infotrieve]</a><!-- /HIGHWIRE --><a name="R11"><!-- null --></a></li><li value="11"> Torbicki A, Kurzyna M, Kuca P, <i>et al.</i> Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. <em>Circulation</em> 2003;108:844–848.<!-- HIGHWIRE ID="31:5:1024:11" --><a href="file:///C:/cgi/external_ref?access_num=10.1161/01.CIR.0000084544.54513.E2&amp;link_type=DOI">[CrossRef]</a><a href="file:///C:/cgi/external_ref?access_num=000184818000013&amp;link_type=ISI">[ISI]</a><a href="file:///C:/cgi/external_ref?access_num=12900346&amp;link_type=MED">[Medline]</a>
<a href="file:///C:/cgi/external_ref?access_num=12900346&amp;displayid=142677&amp;link_type=INFOTRIEVE">[Order article via Infotrieve]</a><!-- /HIGHWIRE --><a name="R12"><!-- null --></a></li><li value="12"> Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. <em>Clin Chim Acta</em> 2005;352:15–35.<!-- HIGHWIRE ID="31:5:1024:12" --><a href="file:///C:/cgi/external_ref?access_num=10.1016/j.cccn.2004.09.001&amp;link_type=DOI">[CrossRef]</a><a href="file:///C:/cgi/external_ref?access_num=000226658600002&amp;link_type=ISI">[ISI]</a><a href="file:///C:/cgi/external_ref?access_num=15653098&amp;link_type=MED">[Medline]</a>
<a href="file:///C:/cgi/external_ref?access_num=15653098&amp;displayid=142677&amp;link_type=INFOTRIEVE">[Order article via Infotrieve]</a><!-- /HIGHWIRE --><a name="R13"><!-- null --></a></li><li value="13"> Alhadi HA, Fox KA. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. <em>QJM</em> 2004;97:187–198.<!-- HIGHWIRE ID="31:5:1024:13" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=qjmed&amp;resid=97/4/187"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R14"><!-- null --></a></li><li value="14"> Puls M, Dellas C, Lankeit M, <i>et al.</i> Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. <em>Eur Heart J</em> 2007;28:224–229.<!-- HIGHWIRE ID="31:5:1024:14" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=ehj&amp;resid=28/2/224"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R15"><!-- null --></a></li><li value="15"> Kaczy&#241;ska A, Pelsers MM, Bochowicz A, Kostrubiec M, Glatz JF, Pruszczyk P. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism. <em>Clin Chim Acta</em> 2006;371:117–123.<!-- HIGHWIRE ID="31:5:1024:15" --><a href="file:///C:/cgi/external_ref?access_num=10.1016/j.cca.2006.02.032&amp;link_type=DOI">[CrossRef]</a><a href="file:///C:/cgi/external_ref?access_num=000240282600017&amp;link_type=ISI">[ISI]</a><a href="file:///C:/cgi/external_ref?access_num=16698008&amp;link_type=MED">[Medline]</a>
<a href="file:///C:/cgi/external_ref?access_num=16698008&amp;displayid=142677&amp;link_type=INFOTRIEVE">[Order article via Infotrieve]</a><!-- /HIGHWIRE --><a name="R16"><!-- null --></a></li><li value="16"> Gali&#232; N, Torbicki A, Barst R, <i>et al.</i> Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. <em>Eur Heart J</em> 2004;25:2243–2278.<!-- HIGHWIRE ID="31:5:1024:16" --><a href="file:///C:/cgi/ijlink?linkType=FULL&amp;journalCode=ehj&amp;resid=25/24/2243"><nobr>[<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R17"><!-- null --></a></li><li value="17"> Coulden R. State-of-the-art imaging techniques in chronic thromboembolic pulmonary hypertension. <em>Proc Am Thorac Soc</em> 2006;3:577–583.<!-- HIGHWIRE ID="31:5:1024:17" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=procats&amp;resid=3/7/577"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R18"><!-- null --></a></li><li value="18"> Klepetko W, Mayer E, Sandoval J, <i>et al.</i> Interventional and surgical modalities of treatment for pulmonary arterial hypertension. <em>J Am Coll Cardiol</em> 2004;43: Suppl. 12 73S–80S.<!-- HIGHWIRE ID="31:5:1024:18" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=jacc&amp;resid=43/12_Suppl_S/73S"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R19"><!-- null --></a></li><li value="19"> Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. <em>Eur Respir J</em> 2001;17:647–652.<!-- HIGHWIRE ID="31:5:1024:19" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=erj&amp;resid=17/4/647"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R20"><!-- null --></a></li><li value="20"> Miyamoto S, Nagaya N, Satoh T, <i>et al.</i> Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. <em>Am J Respir Crit Care Med</em> 2000;161:487–492.<!-- HIGHWIRE ID="31:5:1024:20" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=ajrccm&amp;resid=161/2/487"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R21"><!-- null --></a></li><li value="21"> Bonderman D, Skoro-Sajer N, Jakowitsch J, <i>et al.</i> Predictors of outcome in chronic thromboembolic pulmonary hypertension. <em>Circulation</em> 2007;115:2153–2158.<!-- HIGHWIRE ID="31:5:1024:21" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=circulationaha&amp;resid=115/16/2153"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R22"><!-- null --></a></li><li value="22"> Korff S, Katus HA, Giannitsis E. Differential diagnosis of elevated troponins. <em>Heart</em> 2006;92:987–993.<!-- HIGHWIRE ID="31:5:1024:22" --><a href="file:///C:/cgi/ijlink?linkType=FULL&amp;journalCode=heartjnl&amp;resid=92/7/987"><nobr>[<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R23"><!-- null --></a></li><li value="23"> Gibler WB, Cannon CP, Blomkalns AL, <i>et al.</i> Practical implementation of the Guidelines for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction in the emergency department. <em>Ann Emerg Med</em> 2005;46:185–197.<!-- HIGHWIRE ID="31:5:1024:23" --><a href="file:///C:/cgi/external_ref?access_num=10.1016/j.annemergmed.2005.04.022&amp;link_type=DOI">[CrossRef]</a><a href="file:///C:/cgi/external_ref?access_num=000230855100016&amp;link_type=ISI">[ISI]</a><a href="file:///C:/cgi/external_ref?access_num=16046952&amp;link_type=MED">[Medline]</a>
<a href="file:///C:/cgi/external_ref?access_num=16046952&amp;displayid=142677&amp;link_type=INFOTRIEVE">[Order article via Infotrieve]</a><!-- /HIGHWIRE --><a name="R24"><!-- null --></a></li><li value="24"> Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. <em>Circulation</em> 2007;116:427–433.<!-- HIGHWIRE ID="31:5:1024:24" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=circulationaha&amp;resid=116/4/427"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R25"><!-- null --></a></li><li value="25"> Leuchte HH, Holzapfel M, Baumgartner RA, <i>et al.</i> Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. <em>J Am Coll Cardiol</em> 2004;43:764–770.<!-- HIGHWIRE ID="31:5:1024:25" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=jacc&amp;resid=43/5/764"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R26"><!-- null --></a></li><li value="26"> Nagaya N, Nishikimi T, Uematsu M, <i>et al.</i> Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. <em>Circulation</em> 2000;102:865–870.<!-- HIGHWIRE ID="31:5:1024:26" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=circulationaha&amp;resid=102/8/865"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R27"><!-- null --></a></li><li value="27"> Ishii J, Ozaki Y, Lu J, <i>et al.</i> Prognostic value of serum concentration of heart-type fatty acid-binding protein relative to cardiac troponin T on admission in the early hours of acute coronary syndrome. <em>Clin Chem</em> 2005;51:1397–1404.<!-- HIGHWIRE ID="31:5:1024:27" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=clinchem&amp;resid=51/8/1397"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R28"><!-- null --></a></li><li value="28"> Giannitsis E, Katus HA. Risk stratification in pulmonary embolism based on biomarkers and echocardiography. <em>Circulation</em> 2005;112:1520–1521.<!-- HIGHWIRE ID="31:5:1024:28" --><a href="file:///C:/cgi/ijlink?linkType=FULL&amp;journalCode=circulationaha&amp;resid=112/11/1520"><nobr>[<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R29"><!-- null --></a></li><li value="29"> Rubin LJ, Hoeper MM, Klepetko W, Gali&#232; N, Lang IM, Simonneau G. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. <em>Proc Am Thorac Soc</em> 2006;3:601–607.<!-- HIGHWIRE ID="31:5:1024:29" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=procats&amp;resid=3/7/601"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><a name="R30"><!-- null --></a></li><li value="30"> Bresser P, Pepke-Zaba J, Ja&#239;s X, Humbert M, Hoeper MM. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. <em>Proc Am Thorac Soc</em> 2006;3:594–600.<!-- HIGHWIRE ID="31:5:1024:30" --><a href="file:///C:/cgi/ijlink?linkType=ABST&amp;journalCode=procats&amp;resid=3/7/594"><nobr>[Abstract/<font color="CC0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --></li></ol>


		
        
        
	
	
	
	
	




 










<br clear="ALL">




  <font face="">
  
  </font>
<br clear="ALL">
<br clear="ALL">




	
	
	









<br clear="ALL">


	
	 
		
		
		  
			
	
		<table class="content_box_outer_table">
		
		
			<tbody><tr>
			<td>
		
	

<!-- beginning of inner table -->
	<table class="content_box_inner_table">
<!-- citation -->

	
		




	

	

	
		
			
<tbody><tr><td class="content_box_title_highlight" colspan="2">This Article</td></tr>

	

	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " width="200" height="1" src="./674_files/spacer.gif"></td></tr>
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
				
				<strong><a href="file:///C:/cgi/content/abstract/31/5/1024">
				Abstract</a></strong>
				 					<img alt="Freely available" width="32" height="7" border="0" src="./674_files/free.gif">
				
	
				</td></tr>
			
		
		
	

	
	
	

	
	
	


	
	
	

	
	
	

	
	
	
	
	
	
	
	
	

	
		
		
	
	
		
	

	

	
		
			
		
	

	

	
	 

	
	 

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		
		
		
			
				
				
					<a href="file:///C:/cgi/reprint/31/5/1024">
		<strong>Full Text</strong> (PDF)</a>


				
			
		
		</strong>
		</td></tr>
	
	

	
	
	
	
	

	
	
	

	
	




	
		

	
		

	
		
		

			


	

			

			
		
	

			
	  
	

			

			

			
	
	

	
		
	













	
	
	

	
		
	

	 

	
	
		  
    

	
	
	
	







		
	
		
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="file:///C:/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;saveAlert=no&amp;cited_by_criteria_resid=erj;31/5/1024&amp;return_type=article&amp;return_url=http%3A%2F%2Ferj.ersjournals.com%2Fcgi%2Fcontent%2Ffull%2F31%2F5%2F1024">
				Alert me when this article is cited</a></strong>
			</td></tr>
	

		
		

		
		

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="file:///C:/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;saveAlert=no&amp;correction_criteria_value=31/5/1024&amp;return_type=article&amp;return_url=http%3A%2F%2Ferj.ersjournals.com%2Fcgi%2Fcontent%2Ffull%2F31%2F5%2F1024">
				Alert me if a correction is posted</a></strong>
			</td></tr>
		
























			
		
			
			
			
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
					<strong><a rel="nofollow" href="file:///C:/cgi/citemap?id=erj;31/5/1024">
					Citation Map</a></strong>
				</td></tr>
		
	

			
			
<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " width="200" height="1" src="./674_files/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">Services</td></tr>

	

	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " width="200" height="1" src="./674_files/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="file:///C:/cgi/mailafriend?url=http%3A%2F%2Ferj.ersjournals.com%2Fcgi%2Fcontent%2Ffull%2F31%2F5%2F1024&amp;title=Heart-type+fatty+acid-binding+protein+for+risk+assessment+of+chronic+thromboembolic+pulmonary+hypertension">
				Email this article to a friend</a></strong>
			</td></tr>
			
			


	

	

	

		
		



			
			
			
		
	

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		<a href="file:///C:/cgi/search?qbe=erj;09031936.00100407&amp;journalcode=erj&amp;minscore=5000">
		Similar articles in this journal</a>
		</strong>
		</td></tr>

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="file:///C:/cgi/external_ref?access_num=18256058&amp;link_type=MED_NBRS">
				Similar articles in PubMed</a></strong>
			</td></tr>
		
	


		



			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="file:///C:/cgi/alerts/etoc">
				Alert me to new issues of the journal</a></strong>
			</td></tr>
		

		
		
	

		
		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
			<strong><a href="file:///C:/cgi/citmgr?gca=erj;31/5/1024">
			Download to citation manager</a></strong>
			</td></tr>
		
		
	


	
		
	

	



  			
		


	

	




	





		

		

	
	
	
		


	

	

	


	





	


	
		 
	

		
		
	















	
		
			
				
				
<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " width="200" height="1" src="./674_files/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">Google Scholar</td></tr>

	

	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " width="200" height="1" src="./674_files/spacer.gif"></td></tr>
						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://scholar.google.com/scholar?q=%22author%3AM.+author%3ALankeit%22">
							Articles by Lankeit, M.</a></strong>
						</td></tr>
				
				
			
				
			
				
			
				
			
				
			
				
			
				
			
				
			
				
			
				
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://scholar.google.com/scholar?q=%22author%3AI.%20M.+author%3ALang%22">
							Articles by Lang, I. M.</a></strong>
						</td></tr>
				
				
			
		
		
	
	
	
	

		
			
				
			
		
	










	





	
		
<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " width="200" height="1" src="./674_files/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">PubMed</td></tr>

	

	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " width="200" height="1" src="./674_files/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="file:///C:/cgi/external_ref?access_num=18256058&amp;link_type=PUBMED">
				PubMed Citation</a></strong>
			</td></tr>
		
	

	
		
		
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="file:///C:/cgi/external_ref?access_num=Lankeit+M&amp;link_type=AUTHORSEARCH">
							Articles by Lankeit, M.</a></strong>
						</td></tr>
				
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="Right arrow" width="4" height="11" border="0" src="./674_files/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="file:///C:/cgi/external_ref?access_num=Lang+IM&amp;link_type=AUTHORSEARCH">
							Articles by Lang, I. M.</a></strong>
						</td></tr>
				
			
		

		
	

	
















	















	


































	
		

	

		
			
		
	 
		











	

	






































	</tbody></table>
</td></tr></tbody></table> 


					
					
	

<br clear="ALL">








	
	<p>
	</p><hr noshade="" align="LEFT" width="450" color="#000000" size="1">
	
	<table cellpadding="2" cellspacing="2" width="450">
	<tbody><tr>
		<td align="CENTER" valign="TOP" bgcolor="01396A" nowrap=""><a target="_top" style="text-decoration: none" href="file:///C:/"><font size="-2" color="#FFFFFF" face="trebuchet ms,arial,verdana,helvetica,sans-serif">HOME</font></a></td>
	    <td align="CENTER" valign="TOP" bgcolor="01396A" nowrap=""><a target="_top" style="text-decoration: none" href="file:///C:/help/"><font size="-2" color="#FFFFFF" face="trebuchet ms,arial,verdana,helvetica,sans-serif">HELP</font></a></td>
	    <td align="CENTER" valign="TOP" bgcolor="01396A" nowrap=""><a target="_top" style="text-decoration: none" href="file:///C:/cgi/feedback"><font size="-2" color="#FFFFFF" face="trebuchet ms,arial,verdana,helvetica,sans-serif">FEEDBACK</font></a></td>
	    <td align="CENTER" valign="TOP" bgcolor="01396A" nowrap=""><a target="_top" style="text-decoration: none" href="file:///C:/subscriptions/"><font size="-2" color="#FFFFFF" face="trebuchet ms,arial,verdana,helvetica,sans-serif">SUBSCRIPTIONS</font></a></td>
	    <td align="CENTER" valign="TOP" bgcolor="01396A" nowrap=""><a target="_top" style="text-decoration: none" href="file:///C:/contents-by-date.0.shtml"><font size="-2" color="#FFFFFF" face="trebuchet ms,arial,verdana,helvetica,sans-serif">ARCHIVE</font></a></td>
	    <td align="CENTER" valign="TOP" bgcolor="01396A" nowrap=""><a target="_top" style="text-decoration: none" href="file:///C:/search.dtl"><font size="-2" color="#FFFFFF" face="trebuchet ms,arial,verdana,helvetica,sans-serif">SEARCH</font></a></td>
	    


<td align="CENTER" valign="TOP" bgcolor="01396A" nowrap=""><a target="_top" style="text-decoration: none" href="file:///C:/content/vol31/issue5/"><font size="-2" color="#FFFFFF" face="trebuchet ms,arial,verdana,helvetica,sans-serif">TABLE OF CONTENTS</font></a></td>
	</tr>
	</tbody></table>
	
	

	





</body></html>